NEWS RELEASES
YEAR
-
CANBRIDGE LIFE SCIENCES RECEIVES APPROVAL TO COMMENCE CAN017 IB/III TRIAL IN ESOPHAGEAL SQUAMOUS CELL CANCER (ESCC) IN CHINA
AUG 14, 2018
-
CANBRIDGE LIFE SCIENCES APPOINTS CHIEF MEDICAL OFFICER
JUL 31, 2018
-
CANBRIDGE LIFE SCIENCES APPOINTS VICE PRESIDENT OF CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS AND DIRECTOR OF QUALITY ASSURANCE
MAY 08, 2018
-
CANBRIDGE RECEIVES CHINA FOOD AND DRUG ADMINISTRATION APPROVAL FOR CAN002 AS CANCER ADJUVANT THERAPY
APR 26, 2018
-
CANBRIDGE RECEIVES APPROVAL TO COMMENCE CAN008 PHASE II/III TRIAL IN GLIOBLASTOMA MULTIFORME (GBM) IN CHINA
APR 12, 2018
-
INDUSTRY VETERAN JOINS CANBRIDGE LIFE SCIENCES ADVISORY TEAM
FEB 13, 2018
-
PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA
FEB 02, 2018
-
CANBRIDGE APPOINTS SUNNY ZHANG AS VICE PRESIDENT OF REGULATORY AFFAIRS AND QUALITY
JAN 16, 2018
-
CANBRIDGE LIFE SCIENCES SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR CAN017 TRIAL IN ESOPHAGEAL SQUAMOUS CELL CANCER (ESCC) IN CHINA
DEC 21, 2017
-
CANBRIDGE COMPLETES PATIENT ENROLMENT FOR PHASE I CLINICAL TRIAL OF CAN008 IN TREATMENT OF GLIOBLASTOMA MULTIFORME IN TAIWAN
NOV 30, 2017
